Appili Therapeutics Inc. has released its latest earnings report, shedding light on its financial health and operational progress.
On August 13, 2026, Appili Therapeutics Inc. (APLI.TO) reported its earnings for the fiscal period ending June 30, 2026. The results reflect the company's ongoing challenges and opportunities in the biotechnology sector, particularly in the context of its innovative therapies and funding developments.
Recent earnings trend
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.32M
52W high
$0.04
52W low
$0.01
1W change
-33.33%
Beta
-0.20
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 1400.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+1400.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
238.3%
Annualized
90-Day Vol
232.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.00 – C$0.02 |
| 60 trading days | C$0.01 | C$0.00 – C$0.03 |
| 90 trading days | C$0.01 | C$0.00 – C$0.03 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 4 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | -0.0079 | — | — |
| 2025-12-31 | 2026-02-19 | -0.0074 | — | — |
| 2025-09-30 | 2025-11-20 | -0.0082 | — | — |
| 2025-06-30 | 2025-08-19 | -0.0103 | — | — |
| 2025-03-31 | 2025-06-23 | 0.0019 | — | — |
| 2024-12-31 | 2025-02-14 | -0.0043 | — | — |
Advertisement
Investor takeaway: While Appili's recent earnings show a continuing trend of losses, the company has demonstrated a capacity to exceed analyst expectations in prior quarters. Investors should weigh the company's potential for growth against its current financial state and market conditions.
EPS of -0.0079: A Continued Trend of Losses
Appili's recent EPS figure represents a slight improvement from the year-ago quarter's EPS of -0.02, reflecting a 50% estimated growth, yet it still underscores ongoing challenges in achieving profitability.
Bull case
Appili has a history of surprising analysts with better-than-expected earnings, which suggests it may continue to innovate and secure funding. With a significant NIAID funding award and growing interest in its product LIKMEZ® in the U.S., there’s a chance for recovery and growth ahead.
Bear case
Despite past surprises, Appili's recent EPS of -0.0079 shows that financial difficulties persist. The company's low market cap and ongoing losses may raise concerns about its viability and ability to attract future investment.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
